<p>Biotricity（BTCY）已舉行其第二季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
<h3>認識您的 ETF AI 分析師</h3>
<ul>
<li>瞭解 TipRanks 的_ETF_ AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 所揭示的見解。</li>
</ul>
<p>Biotricity 最近的財報電話會議傳達了強烈的積極情緒，突顯了顯著的收入增長、改善的毛利潤和正向的 EBITDA。儘管出現了淨虧損和運營費用增加，但戰略進展和積極的財務趨勢表明公司前景樂觀。</p>
<h2>收入增長</h2>
<p>在 2026 財年的第二季度，Biotricity 報告的收入較去年同期增長了 19%，達到 390 萬美元。這一增長凸顯了公司成功的市場策略和服務的日益普及。</p>
<h2>毛利潤改善</h2>
<p>該季度公司的毛利潤總計 320 萬美元，比去年同期增長了 29.4%。毛利潤率提高了 660 個基點，達 81.9%，反映了公司的運營效率和成本管理。</p>
<h2>正向 EBITDA</h2>
<p>Biotricity 連續第二個季度實現了 373,000 美元的正向 EBITDA，標誌着朝着全面盈利的進展。這一成就突顯了公司有效的財務管理和運營策略。</p>
<h2>心臟監測技術的進展</h2>
<p>Biocore Pro 2 心臟監測儀的開發以及 Biocore Pro 銷售的擴展，包括與醫院網絡和診所的試點項目，展示了 Biotricity 在醫療保健領域對創新和技術進步的承諾。</p>
<h2>戰略合作伙伴關係和市場擴展</h2>
<p>Biotricity 擴大了在退伍軍人事務部和領先家庭護理集團的覆蓋範圍，並在肺部和神經學領域建立了合作伙伴關係。這些戰略舉措預計將增強公司的市場存在感和增長潛力。</p>
<h2>歸屬於普通股東的淨虧損</h2>
<p>該財年的三個月淨虧損為 772,000 美元，較去年同期的 160 萬美元有所改善。這一淨虧損的減少表明公司財務健康狀況的改善。</p>
<h2>運營費用增加</h2>
<p>第二季度的運營費用較去年同期增加了 5.1%，達到 290 萬美元。儘管費用增加，公司仍繼續專注於成本管理和運營效率。</p>
<h2>前瞻性指導</h2>
<p>Biotricity 的前瞻性指導強調持續增長和盈利能力。公司旨在利用規模經濟，並將利潤投資於擴大市場份額和商業團隊。通過專注於創新、戰略合作伙伴關係和商業擴展，Biotricity 有望實現持續增長。</p>
<p>總之，Biotricity 的財報電話會議反映了強烈的積極情緒，得益於顯著的收入增長、改善的毛利潤和正向的 EBITDA。公司的戰略進展和對創新的關注使其在未來成功的道路上處於良好位置，儘管面臨淨虧損和運營費用增加等挑戰。</p>

BTCY

<p>Biotricity 第二季度的財報電話會議強調了顯著的收入增長，增長率為 19%，達到 390 萬美元，毛利潤提高了 29.4%，達到 320 萬美元，且 EBITDA 為 37.3 萬美元，呈現正值。儘管淨虧損為 77.2 萬美元，且運營費用增加，但在心臟監測技術和市場擴展方面的戰略進展表明了良好的前景。公司旨在通過創新和戰略合作伙伴關係實現持續增長和盈利</p>

<p>Biotricity ((BTCY)) has held its Q2 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Biotricity（BTCY）已舉行其第二季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>認識您的 ETF AI 分析師</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>瞭解 TipRanks 的_ETF_ AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 所揭示的見解。</li>
</ul>
</div><p>Biotricity’s recent earnings call conveyed a strong positive sentiment, highlighting significant revenue growth, improved gross profit, and positive EBITDA. Despite a net loss and increased operating expenses, the strategic advancements and positive financial trends suggest a promising outlook for the company.</p>
<div class="lb-trans"><p>Biotricity 最近的財報電話會議傳達了強烈的積極情緒，突顯了顯著的收入增長、改善的毛利潤和正向的 EBITDA。儘管出現了淨虧損和運營費用增加，但戰略進展和積極的財務趨勢表明公司前景樂觀。</p>
</div><h2>Revenue Growth</h2>
<div class="lb-trans"><h2>收入增長</h2>
</div><p>For the second quarter of fiscal ’26, Biotricity reported a 19% increase in revenue compared to the corresponding period in the previous year, reaching $3.9 million. This growth underscores the company’s successful market strategies and increasing adoption of its services.</p>
<div class="lb-trans"><p>在 2026 財年的第二季度，Biotricity 報告的收入較去年同期增長了 19%，達到 390 萬美元。這一增長凸顯了公司成功的市場策略和服務的日益普及。</p>
</div><h2>Improved Gross Profit</h2>
<div class="lb-trans"><h2>毛利潤改善</h2>
</div><p>The company’s gross profit for the quarter totaled $3.2 million, marking a 29.4% increase from the prior year period. The gross profit percentage improved by 660 basis points to 81.9%, reflecting the company’s operational efficiencies and cost management.</p>
<div class="lb-trans"><p>該季度公司的毛利潤總計 320 萬美元，比去年同期增長了 29.4%。毛利潤率提高了 660 個基點，達 81.9%，反映了公司的運營效率和成本管理。</p>
</div><h2>Positive EBITDA</h2>
<div class="lb-trans"><h2>正向 EBITDA</h2>
</div><p>Biotricity achieved a positive EBITDA of $373,000 for the second consecutive quarter, signaling progress towards full profitability. This achievement highlights the company’s effective financial management and operational strategies.</p>
<div class="lb-trans"><p>Biotricity 連續第二個季度實現了 373,000 美元的正向 EBITDA，標誌着朝着全面盈利的進展。這一成就突顯了公司有效的財務管理和運營策略。</p>
</div><h2>Advancements in Cardiac Monitoring Technology</h2>
<div class="lb-trans"><h2>心臟監測技術的進展</h2>
</div><p>The development of the Biocore Pro 2 cardiac monitor and the expansion of Biocore Pro sales, including pilot programs with hospital networks and clinics, demonstrate Biotricity’s commitment to innovation and technology advancement in healthcare.</p>
<div class="lb-trans"><p>Biocore Pro 2 心臟監測儀的開發以及 Biocore Pro 銷售的擴展，包括與醫院網絡和診所的試點項目，展示了 Biotricity 在醫療保健領域對創新和技術進步的承諾。</p>
</div><h2>Strategic Partnerships and Market Expansion</h2>
<div class="lb-trans"><h2>戰略合作伙伴關係和市場擴展</h2>
</div><p>Biotricity expanded its reach into VA and leading home care groups, as well as forming partnerships in pulmonary and neurology sectors. These strategic moves are expected to enhance the company’s market presence and growth potential.</p>
<div class="lb-trans"><p>Biotricity 擴大了在退伍軍人事務部和領先家庭護理集團的覆蓋範圍，並在肺部和神經學領域建立了合作伙伴關係。這些戰略舉措預計將增強公司的市場存在感和增長潛力。</p>
</div><h2>Net Loss Attributable to Common Shareholders</h2>
<div class="lb-trans"><h2>歸屬於普通股東的淨虧損</h2>
</div><p>The net loss for the fiscal 3-month period was $772,000, an improvement from $1.6 million in the prior year period. This reduction in net loss indicates progress in the company’s financial health.</p>
<div class="lb-trans"><p>該財年的三個月淨虧損為 772,000 美元，較去年同期的 160 萬美元有所改善。這一淨虧損的減少表明公司財務健康狀況的改善。</p>
</div><h2>Increase in Operating Expenses</h2>
<div class="lb-trans"><h2>運營費用增加</h2>
</div><p>Operating expenses for the second quarter increased by 5.1% to $2.9 million compared to the same period last year. Despite this increase, the company continues to focus on cost management and operational efficiency.</p>
<div class="lb-trans"><p>第二季度的運營費用較去年同期增加了 5.1%，達到 290 萬美元。儘管費用增加，公司仍繼續專注於成本管理和運營效率。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指導</h2>
</div><p>Biotricity’s forward-looking guidance emphasizes continued growth and profitability. The company aims to leverage its economies of scale and invest profits into expanding its market share and commercial team. With a focus on innovation, strategic partnerships, and commercial expansion, Biotricity is poised for sustained growth.</p>
<div class="lb-trans"><p>Biotricity 的前瞻性指導強調持續增長和盈利能力。公司旨在利用規模經濟，並將利潤投資於擴大市場份額和商業團隊。通過專注於創新、戰略合作伙伴關係和商業擴展，Biotricity 有望實現持續增長。</p>
</div><p>In summary, Biotricity’s earnings call reflects a strong positive sentiment, driven by significant revenue growth, improved gross profit, and positive EBITDA. The company’s strategic advancements and focus on innovation position it well for future success, despite challenges such as net loss and increased operating expenses.</p>
<div class="lb-trans"><p>總之，Biotricity 的財報電話會議反映了強烈的積極情緒，得益於顯著的收入增長、改善的毛利潤和正向的 EBITDA。公司的戰略進展和對創新的關注使其在未來成功的道路上處於良好位置，儘管面臨淨虧損和運營費用增加等挑戰。</p>
</div>

Biotricity 的財報電話會議：增長與樂觀前景